Collectively, our preclinical data, consistent with the clinical results, pointed to a critical contribution of CD4+ T cells associated with the MHCII upregulation on tumor cells and intratumoral immune cells to GBM control and patient survival after oHSV therapy. This evidence concerns the gene CD4 and glioblastoma.